Stockscreener 앱 받기
3.50
3.31%
-0.12
시간 외 거래:
3.57
0.07
+2.00%
전일 마감가:
$3.62
열려 있는:
$3.59
하루 거래량:
1.47M
Relative Volume:
1.04
시가총액:
$578.34M
수익:
$361.51M
순이익/손실:
$102.18M
주가수익비율:
5.8587
EPS:
0.5974
순현금흐름:
$112.21M
1주 성능:
+1.16%
1개월 성능:
-11.84%
6개월 성능:
-15.15%
1년 성능:
+133.33%
1일 변동 폭
$3.45
$3.64
1주일 범위
$3.45
$3.695
52주 변동 폭
$1.4705
$5.78
아이언우드 제약 Stock (IRWD) Company Profile
명칭
Ironwood Pharmaceuticals Inc
전화
617-621-7722
주소
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.50 | 578.34M | 361.51M | 102.18M | 112.21M | 0.5974 |
TAK
Takeda Pharmaceutical Co Adr
|
20.91 | 66.81B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
42.09 | 49.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.66 | 38.08B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.72 | 32.94B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
598.72 | 25.68B | 3.17B | 1.29B | 1.01B | 27.09 |
아이언우드 제약 Stock (IRWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-08 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 개시 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Wells Fargo | Overweight |
| 2023-11-09 | 개시 | Jefferies | Buy |
| 2023-09-28 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-02 | 개시 | CapitalOne | Overweight |
| 2022-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 개시 | Northland Capital | Outperform |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-11-07 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 개시 | H.C. Wainwright | Sell |
| 2018-05-09 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2017-07-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 개시 | Wells Fargo | Outperform |
| 2017-04-07 | 재확인 | Mizuho | Buy |
| 2017-02-22 | 재확인 | Barclays | Equal Weight |
| 2016-11-04 | 재확인 | Mizuho | Buy |
| 2016-10-24 | 재확인 | Wedbush | Neutral |
| 2016-10-10 | 재확인 | Mizuho | Buy |
| 2016-09-27 | 재확인 | WallachBeth | Hold |
모두보기
아이언우드 제약 주식(IRWD)의 최신 뉴스
Bank of America reports an Ironwood Pharmaceuticals (IRWD) stake with no sole voting power. - Stock Titan
Ironwood Pharmaceuticals, Inc. Estimates – NASDAQ:IRWD - TradingView
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer - BioSpace
Ironwood Pharmaceuticals Appoints Tammi Gaskins as CEO Effective January 2027 - Kalkine Media
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer - Business Wire
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Zacks Investment Research
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com Australia
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com Nigeria
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com India
83,306 shares to cover taxes: Ironwood Pharmaceuticals (IRWD) ex-officer proposes a sale - Stock Titan
Ironwood Pharmaceuticals Director Alexander J. Denner Awarded 3,694 Shares Under Compensation Policy - Kalkine Media
Ironwood: Medicare Is Not The Problem I Thought It Was - Seeking Alpha
Ironwood Pharmaceuticals at Wells Fargo conference: linzess rebound drives turnaround - Investing.com Canada
Ironwood Pharmaceuticals at Wells Fargo conference: linzess rebound drives turnaround - Investing.com UK
IRWD Stock Price, Quote & News - Syfe
IRWD stock gains as Wells Fargo conference spotlight shifts to cash flow - ad-hoc-news.de
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Ironwood Pharmaceuticals Inc. Class A (IRWD) Peer Comparison – Compare with Others - Value Research
Ironwood Pharmaceuticals (IRWD) Slips 2.6% as Shares Approach Key Support at $3.92Backspread Trade - vinanet.vn
Ironwood Pharmaceuticals (IRWD) Slips 2.59% to $4.13: Analyzing Key Support and Resistance LevelsETF Flow - dars.gov.et
Ironwood Pharmaceuticals Inc. Class A (IRWD) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Ironwood Pharmaceuticals: High Dependence On Its Next Trial (NASDAQ:IRWD) - Seeking Alpha
Ironwood (IRWD) Results Versus Estimates: EPS Does Not Reach the Reported Estimate for the Current Session; Market Move: The Market Price Moves 1.16% Higher in Latest TradingEarnings Yield Analysis - vinanet.vn
Ironwood Pharmaceuticals (IRWD) Edges Higher: Shares Advance 1.16% as Bulls Defend Key SupportRSI Oversold Picks - vinanet.vn
Ironwood Pharmaceuticals (IRWD) Edges Higher: Shares Advance 1.16% as Bulls Defend Key SupportValue ETF - dars.gov.et
Jeffrey Silber Net Worth (2026) - GuruFocus
Bank of America Corp DE Sells 2,838,753 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo
Ironwood Pharmaceuticals (IRWD) Q2 2026 Earnings: EPS Misses Estimates, Stock Climbs 5.64%Dividend Growth Analysis - vinanet.vn
Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake - stocktitan.net
Dimensional Fund Advisors LP Raises Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownTime to Sell? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Amundi - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
State Street Corporation (NYSE: IRWD caretaker) holds 5.4% of Ironwood common stock - Stock Titan
Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pacer Advisors Inc. Makes New $3.98 Million Investment in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised - Eastern Progress
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call High - GuruFocus
Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed? - Yahoo! Finance Canada
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ... - Yahoo Finance
IRWD Looks 15.8% Undervalued on GF Value™ as Debt Reduction Effo - GuruFocus
Ironwood Pharmaceuticals Q2 Earnings Call Highlights - Yahoo Finance
Ironwood Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-08-06 - Seeking Alpha
Is Ironwood Pharmaceuticals (IRWD) Undervalued After Q2 Earnings - GuruFocus
IRWD: LINZESS sales surged and guidance was raised as apraglutide advanced in phase III trials - TradingView
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates - Yahoo Finance
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
아이언우드 제약 (IRWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아이언우드 제약 주식 (IRWD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RONALD SILVER | Officer |
Jul 07 '26 |
Proposed Sale |
4.38 |
127,890 |
560,158 |
0 |
| Silver Ronald | PFO & PAO |
Jul 07 '26 |
Sale |
4.52 |
127,890 |
578,063 |
313,680 |
| McHugh Julie | Director |
Jun 16 '26 |
Sale |
3.73 |
21,571 |
80,460 |
250,749 |
| JULIE MCHUGH | Director |
Jun 16 '26 |
Proposed Sale |
3.69 |
21,571 |
79,597 |
0 |
| DENNER ALEXANDER J | Director |
Mar 17 '26 |
Sale |
3.05 |
6,730,800 |
20,530,448 |
9,188,635 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 24 '26 |
Sale |
3.66 |
103,526 |
378,905 |
1,489,002 |
| Silver Ronald | Principal Accounting Officer |
Feb 24 '26 |
Sale |
3.66 |
12,621 |
46,193 |
252,636 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,239 |
41,135 |
213,738 |
| Martini Gregory S. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,457 |
41,933 |
160,601 |
| John Minardo | Chief Legal Officer |
Feb 24 '26 |
Sale |
3.66 |
19,053 |
69,734 |
363,886 |
3.16%
자본화:
|
볼륨(24시간):